CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigated for use/treatment in cancer/tumors (unspecified).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.